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Background: Urinary tract infection (UTI) is a common medical condi-
tion among women. E. coli is the most common causative organism. 
Appropriate understanding of the development of antimicrobial resis-
tance over the past helps to establish efficient treatment strategies in 
the future. The study aims to determine the antimicrobial resistance 
trends exhibited by E. coli isolates from women urine cultures over 
the past 10 years.
Methods: A total of 1874 positive urine samples over the years 2009 
to 2018 were reviewed and classified according to the response to 24 
different antimicrobial drugs in the laboratory. Relations between time 
and resistance evolutionary profiles were calculated. 
Results: Gentamicin (p value =0.039),amoxicillin(p value =0.017), ce-
foxitin (p value =0.001) and cefixime (p value =0.026) fulfilled satis-
factory figures in terms of average resistance, regression of resistance, 
speed of resistance evolution, steadiness of performance, side effects, 
spectrum range and cost with high significance. 
Conclusion: Antibiotics that showed satisfactory susceptibility in cul-
ture are recommended for future treatment protocols of urinary tract 
infection in Jordan.
Trends of antimicrobial resistance 
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Introduction
Antimicrobial resistance is a mounting threat to 
human societies [1]. Understanding the patterns of 
resistant traits evolution and regression according 
to the change in the treatment protocols and an-
timicrobial usage gives strong predictions of how 
the resistance course will change over time, which 
helps in reformulating future strategies that could 
slow the progression of resistance.
Escherichia coli is one of the most commonly 
opportunistic bacteria associated with humans 
today [2]. When E. coli is exposed to antibiotics, 
their cells developing resistant traits to survive and 
reproduce rapidly [3]. Prolonged exposure to anti-
biotics increases the activity of specific regulatory 
proteins that work on gene segments leading to 
the extrusion of antimicrobials out of the bacterial 
cell before reaching their target organelles [3]. The 
fastest way for bacteria to acquire resistance is 
through cell horizontal transfer of genetic struc-
tures called plasmids that contain specific DNA 
segments [4]. Plasmids can spread through an 
entire community of bacterial population within 
about 30 minutes [4]. They are capable of sharing 
genetic segments for specific efflux pumps that 
work on the cell wall of the bacteria to extru-
de antimicrobial molecules [5]. Bacteria can lose 
their acquired resistance if the selective pressure 
applied is changed or eliminated but this biologi-
cal process occurs more slowly [6].
Urinary tract infections (UTI) due to E. coli oc-
curs mostly in the lower parts of urinary system, 
the bladder and the urethra, causing cystitis and 
urethritis respectively. At times, it can be transferred 
to the kidneys causing pyelonephritis [7]. Women 
have much higher chance of acquiring UTI than 
men because they have a shorter urethra, since E. 
coli is heavily present in fecal matter, and can easily 
be transferred to the urethra through the urethral 
opening [8]. Infection can occur by sexual contact 
[9], improper wiping techniques after defecation; 
wiping from back to front [9] and holding of urine; 
frequent urination allows flushing of E. coli and 
decreases the risk of infection [10]. Many other di-
rect causes of infection can be present, like having 
a urinary catheter, using birth control methods or 
taking regular courses of antibiotics [11]. 
A total of 1-3% of all medical consultations in Great 
Britain compromises UTIs [12]. E. coli, on average is 
responsible for nearly 85% of UTI infections [13]. The 
average annual UTIs is 150 million cases globally [11]. 
Although the average is rising in both sexes, the in-
crease rate in women is twice as men [14]. A total of 
60% of women worldwide are estimated to develop 
UTI at least once in their lifetime [15]. Recent studies 
in Jordan, reported increased antibiotics resistance 
among E. coli uropathogens [16]. 
The aim of this study is to present a useful infor-
mative data for future establishment of antimicro-
bial usage in Jordan. To the best of our knowledge, 
this is the first study in Jordan to incorporate data 




This study was conducted at The Jordan University 
Hospital (JUH), a tertiary hospital in Amman, Jor-
dan. It gained acceptance by the Institutional Re-
view Board (IRB No.10/2019/25180). Our inclusion 
criteria consisted of nonpregnant women who re-
gularly visited JUH and were covered by the hospi-
tal insurance system. This is to ensure that patients 
followed unified treatment protocols and strategies 
and the bacterial urine cultures were subjected to 
the same laboratory conditions over the 10 years 
period. Men were excluded due to anatomical 
variables and different aetiologias and treatment 
protocols. Other body fluid cultures were excluded 
due to different treatment strategies. Table 1 shows 
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Table 1.  Antimicrobial drugs arranged according to 
their market availability in Jordan and cu-





Current role in treatment 
protocols [18]
Amikacin 2009-2018 Resistant ESBL infections 
Amoxicillin 2009-2018
First line agent in UTI in 
pregnancy 
Ampicillin 2012-2018 First line agent in pregnancy 
Cefepime 2009-2012 No current role
Cefixime 2015-2018 No current role
Cefotaxime 2011-2018 No current role
Cefoxitin 2017-2018 Second line agent for cystitis
Cefpodoxime N/A No current role 
Ceftazidime N/A No current role
Ceftriaxone 2009-2018
First line agent in severely ill 
patients, Third line agent in 
pyelonephritis 
Cefuroxime 2009-2018 Second line agent for cystitis
Cephalothin N/A
Second line agent for cystitis 
and UTI in pregnancy 
Ciprofloxacin 2009-2018
Second line agent for 
pyelonephritis
Cotrimoxazole 2011-2018
First line agent for cystitis and 
pyelonephritis
Ertapenem 2010-2018
Severe, complicated and 
resistant pyelonephritis, ESBL 
infection
Gentamicin 2009-2018
Second line agent in severely 
ill patients
Imipenem 2009-2018
Severe, complicated and 
resistant pyelonephritis, ESBL 
infection
Meropenem 2009-2018 No current role
Nalidixic acid N/A No current role
Nitrofurantoin 2009-2016
First line agent for cystitis and 
UTI in pregnancy




Severe, complicated and 
resistant infections
Tetracycline 2009-2018 No current role
Tobramycin 2009-2018 No current role
the list of enrolled 24 antibiotics, the sample size 
for each antibiotic, the years of market availability 
in Jordan and the current role in UTI treatment 
protocols.
Data collection and analysis
Retrospective collection of 1874 urine sample results 
from January 2009 to December 2018 was done. 
Culture and sensitivity reports were obtained from 
the records of Microbiology Department at The 
JUH. Response of E. coli to 24 different antibiotics 
was categorized to susceptible (S) or resistant (R). 
Susceptibility or resistance to extended spectrum β 
lactamase (ESBL) results were interpreted according 
to the Clinical Laboratory Standard Institute (CLSI) 
2017 protocols [19]. ESBL percentages were calcu-
lated since the start of conducting the test (May, 
2017 to December, 2018).
Data was analyzed by SPSS version 23 program 
and presented by Microsoft Excel program, office 
2019. Descriptive statistics and frequencies were 
applied. Moreover, linear regression analysis was 
done to investigate the change in resistance over 
ten years and Pearson’s r was calculated. P-value < 
0.05 was considered to indicate statistically signifi-
cant difference.
Interpretation
Results interpretation took accredited international 
and national antimicrobial resistance recommen-
dations into consideration. Antimicrobial market 
drug availability and usage during the 10-year pe-
riod was also considered. Final recommendations 
for future treatment protocols were constructed 
using rationale of antimicrobial stewardship stra-
tegy formulary restrictions accredited by Ontario 
public health [20]. North York general antimicro-
bial restriction guidelines (accredited in 2015) are 
applied in JUH and were also taken into conside-
ration [21]. 
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Table 2. The percentage of antimicrobial resistant E. coli isolates among the total number of samples per year.
Year
2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
n r % n r % n r % n r % n r % n r % n r % n r % n r % n r %
Amikacin 13 7.69 19 21.05 22 9.09 55 38.18 70 5.71 212 8.49 162 14.81 160 14.38 103 4.85 18 27.78
Amoxicillin 89 75.28 123 70.73 157 82.80 142 82.39 158 75.32 264 81.82 239 69.87 219 69.41 237 45.15 246 32.11
Ampicillin - - - - - - - - - - - - - - - - 136 78.68 221 71.04
Cefepime - - - - - - - - - - - - - - - - 135 72.59 221 64.25
Cefixime 13 53.85 19 68.42 22 77.27 55 69.09 70 68.57 212 49.06 162 41.98 160 44.38 103 30.10 18 27.78
Cefotaxime 88 43.18 123 35.77 157 42.04 142 38.03 158 44.94 264 50.38 239 43.51 219 52.05 101 46.53 31 48.39
Cefoxitin 13 69.23 19 89.47 22 100.00 55 72.73 71 78.87 211 54.03 161 54.04 160 59.38 235 40.43 244 40.57
Cefpodoxime 13 30.77 19 31.58 22 31.82 55 25.45 71 23.94 211 20.85 161 13.04 160 24.38 235 16.17 242 11.98
Ceftazidime - - - - - - - - - - - - - - - - 135 40.74 221 40.27
Ceftriaxone 13 61.54 19 73.68 22 86.36 55 70.91 70 65.71 212 51.89 162 44.44 160 55.63 236 39.41 244 40.57
Cefuroxime 13 69.23 19 89.47 22 100.00 55 72.73 70 78.57 212 54.72 162 54.94 160 61.88 103 37.86 21 38.10
Cephalothin 88 44.32 123 38.21 157 45.22 142 50.70 158 50.00 264 57.58 239 44.35 219 53.42 234 45.73 244 44.26
Ciprofloxacin 13 76.92 19 78.95 22 95.45 55 74.55 69 66.67 211 47.39 162 45.68 160 47.50 236 29.24 244 28.69
Cotrimoxazole 89 57.30 123 60.98 157 61.15 142 59.86 158 54.43 264 60.98 239 54.81 219 62.10 237 53.59 245 46.12
Ertapenem - - 9 22.22 19 10.53 55 0.00 70 1.43 212 2.36 162 2.47 160 0.63 103 0.97 18 5.56
Gentamicin 89 25.84 124 27.42 157 26.75 142 19.01 158 17.09 264 26.89 239 20.50 219 21.46 236 19.49 246 16.26
Imipenem 13 0.00 19 5.26 22 0.00 55 0.00 70 0.00 211 1.90 162 1.23 160 1.88 236 0.42 242 0.83
Meropenem - - - - - - - - - - - - - - - - 136 0.00 222 0.45
Results
The mean age of patients was 37.1 ± 14.6 years. 
Median age was 32 years. Among 26537 collec-
ted urine samples, 9970 (37.6%) samples showed 
bacterial growth. After exclusion of mixed growth 
samples. Out of 4164 samples were left, 1874 sam-
ples showed E. coli growth (45%). Annual results 
of sensitivity and resistance to each antibiotic are 
shown in Table 2.
Analysis of data collected showed that 10 out 
of 24 antibiotics have P-values of less than 0.05 as 
shown in Table 3. Out of these ten antibiotics, the 
highest average resistance rate was to amoxicillin 
(68.5%; P-value=0.017) followed by cefotaxime and 
ceftriaxone with average resistance rates of (65.9% 
and 65.7%, respectively) and P-value of 0.004 and 
0.452, respectively, while the average resistance rate 
to gentamicin was (22.1%; P-value =0.039).
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Year
2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
n r % n r % n r % n r % n r % n r % n r % n r % n r % n r %
Nalidixic acid 89 57.30 123 56.10 157 57.32 142 59.86 158 56.33 264 68.18 239 65.27 219 66.67 100 68.00 21 66.67
Nitrofurantoin 89 3.37 123 2.44 157 8.92 142 23.94 158 32.91 264 39.77 239 17.99 219 33.79 237 24.47 246 17.07
Norfloxacin 88 32.95 123 35.77 157 34.39 142 35.21 158 34.81 264 41.67 239 38.08 219 42.47 237 32.07 245 27.35
Piperacillin / 
tazobactam
- - - - - - - - - - - - - - - - 134 11.19 222 8.11
Tetracycline - - - - - - - - - - - - - - - - 133 52.63 221 47.51
Tobramycin - - - - - - - - - - - - - - - - 133 18.80 219 15.98
n: Total sample numbers; r%: Percent of resistant cases.
Antibiotic
Average resistance
P value Pearson’s r Variance Trend 
%
Amikacin 15.20 0.902 0.045 0.011746 +
Amoxicillin* 68.50 0.017 -0.726 0.028271 -
Ampicillin 74.90 - - -  
Cefepime** 53.00 0.004 -0.814 0.030014 -
Cefixime* 44.50 0.026 0.693 0.002643 +
Cefotaxime** 65.90 0.004 -0.817 0.039546 -
Cefoxitin** 23.00 0.001 -0.879 0.00547 -
Cefpodoxime 40.50 - - -  
Ceftazidime** 59.00 0.005 -0.801 0.023945 -
Ceftriaxone** 65.70 0.004 -0.817 0.041746 -
Cefuroxime 47.40 0.452 0.269 0.00309 +
Cephalothin 68.40 - - -  
Ciprofloxacin** 59.10 0 -0.916 0.051082 -
Cotrimoxazole 57.10 0.083 -0.574 0.002493 -
Antibiotic
Average resistance
P value Pearson’s r Variance Trend 
%
Ertapenem 5.10 0.094 -0.59 0.005173 -
Gentamicin* 22.10 0.039 -0.656 0.001838 -
Imipenem 1.20 0.722 -0.129 0.000266 -
Meropenem 0.30 - - -  
Nalidixic acid** 62.20 0.002 0.855 0.002708 +
Nitrofurantoin 20.50 0.095 0.556 0.016684 +
Norfloxacin 35.50 0.816 -0.085 0.001997 -
Piperacillin / 
tazobactam
9.70 - - -  
Tetracycline 50.10 - - -  
Tobramycin 17.40 - - -  
Table 3.  The average antibiotic resistance of E. coli isolates, P -value, Pearson’s r, variance and trend for each antibiotic over the 10-year period.
*: A significance of < 0.05 is marked by , **: while if < 0.005, it is marked by 
. P- value, Pearson’s r, variance and trend were not calculated for antimicrobial drugs that were 
tested through a period of ≤ 2 years.
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Overall trends of antimicrobial resistance were 
noticed to be positive for five antibiotics (amika-
cin, nitrofurantoin, nalidixic acid, cefuroxime and 
cefixime) but negative for other twelve antibiotics 
(gentamicin, cotrimoxazole, ciprofloxacin, norfloxa-
cin, amoxicillin, imipenem, ertapenem, cefoxitin, 
ceftazidime, cefotaxime, ceftriaxone and cefepime). 
Figure 1 shows trends of antimicrobial resistance in 
E. coli isolates for antibiotics with significant P-value 
of < 0.05.
The remaining seven antibiotics (tobramycin, 
tetracycline, piperacillin / tazobactam, ampicillin, 
meropenem, cephalothin and cefpodoxime) were 
tested at The JUH laboratories for only two years 
(2017-2018). Through this period, the average re-
sistance to ampicillin was the highest among this 
group of antibiotics and among all 24 antibiotics too 
with average resistance rate of (74.9%) while mero-
penem had the least average resistance rate (0.3%).
ESBL positivity test was added by The JUH labo-
ratory protocols in the period from May 2017 to 
December 2018. Results of positive and negative 
ESBL were calculated monthly. The average rate of 
positive ESBL strains of E. coli over 20 months was 
(33.1%) and its overall trend was positive as shown 
in Figure 2. 
Discussion
Many concerns have been rising due to the emer-
gence of new bacterial strains that are resistant to 
multiple antibiotics which are considered as the 
first line of treatment in UTI. The most common 
among these strains is the ESBL producers, which 
has developed resistance against penicillins and te-
tracyclines [22]. ESBL adaptation still has not wor-
ked against carbapenems [22], whereas many other 
resistant strains of E. coli are rising in recent years. 
For example, UTIs caused by ciprofloxacin-resistant 
E. coli have increased from 3% to 17% between the 
years 2000 to 2010 [23], pushing up the importance 
Figure 1:  Overall trends of E. coli resistance 2009-
2018.
Figure 2:  Percentages of ESBL in the period from May 2017 to December 2018.
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of understanding the patterns of resistance in this 
type of bacteria and the urge to counter it.
The accredited protocols for prescribing antibio-
tics in JUH are according to the recommendations 
of National Antimicrobial Resistance Plan [24], 
World Health Organization (WHO) Antimicrobial 
Resistance (AMR) Plan [25], Joint Commission In-
ternational (JCI) protocols of antimicrobial descrip-
tions [26], and Pharmaceutical drugs description 
and awareness protocols of pharmacy department 
at The JUH [27].
In this study, we will discuss each antimicrobial 
class on an individual basis as follow:
Amikacin
It can be used as a therapeutic option for resis-
tant ESBL E. coli isolates in case of limited resources 
[28]. Following accreditation of AMR plan in 2016, 
amikacin has shown minimal variance in resistance 
profiles.
Gentamicin
E. coli resistance to gentamicin can vary on insti-
tutional basis [29]. There is a slow trending down 
in resistance with overall low average resistance 
(22.1%). Gentamicin is used as a second line agent 
in severely ill patients. AMR plans restricted the usa-
ge of gentamicin to severe infections; this approach 
may has helped in the low rate of resistance values 
following 2016.
Tobramycin and tetracycline
Both have no current role in UTI treatment guide-
lines [18], but this approach should follow further 
studies on their performances in the following years. 
Cotrimoxazole
It has an overall negative trend and is used as a first 
line agent. Cotrimoxazole has shown steadiness in 
performance over many years even to other 
E. coli infections [30]. Though it has a high ave-
rage resistance (57.1%), the application of good an-
timicrobial usage plans could control the resistance 
towards it as shown in the years following 2016. 
Nitrofurantoin
It showed a great increase in resistance between 
the years of 2009 (3.4%) to 2014 (39.8%) followed 
by a period of slow regression in resistance sin-
ce nitrofurantoin was unavailable in The JUH du-
ring the years 2015-2017. This fact may explaining 
the mild regression in resistance that took place 
in the following years. The overall trend of resis-
tance is positive which emphasizes the revision of 
treatment protocols that consider nitrofurantoin as 
a first line agent. This antibiotic is also recommen-
ded for empiric therapy for community-acquired 
and nosocomial lower UTI caused by E. coli sus-
ceptible to it. Additionally, nitrofurantoin is also 
active against most strains of multidrug-resistant 
gram-negative bacilli including most ESBL-produ-
cing strains except Proteus spp. and Pseudomonas 
aeruginosa [31].
Ciprofloxacin
There is an evident increase in resistance in the pe-
riod 2009 (76.9%) to 2011 (95.5%), then a near 
steady state took over in the years 2012 to 2016, 
followed by regression of resistance in the following 
years. Though the average resistance of ciprofloxa-
cin remains high (59.1%), and the overall trend of 
resistance is negative which makes ciprofloxacin 
a reliable antimicrobial choice. It is evident that a 
significant drop in resistance followed the accre-
ditation of AMR plans in 2016. Ciprofloxacin is a 
good candidate for present and future strategies in 
treating UTIs caused by E. coli. Though its resistan-
ce has regressed. Rates of ciprofloxacin resistant of 
uropathogenic E. coli in this study and other Jor-
danian studies are much higher than many other 
studies worldwide [23]. A recent study carried out 
in Jordan has indicated alarming high rates recovery 
of multi-drug resistant uropathogenic E. coli from 
Jordanian patients associated with high rates of 
positive ST131 clone and fluoroquinolone resistant 
and important types of blaCTX-M [16]. Also, it has 
been shown that multi-drug resistant E. coli to 3 or 
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more antibiotic classes causing urinary tract infec-
tions will be often associated with treatment failure, 
particularly in association with bacterial strains ca-
rrying CTX-M extended spectrum β-lactamases [32]. 
In addition, it has been reported that CTX-M-15 
extended spectrum β-lactamases encoding genes 
are widely spread among Enterobacteriaceae in the 
Middle Eastern region [33]. 
Norfloxacin and Nalidixic acid
Though both drugs have high average resistance 
(35.5% and 62.2%, respectively), the resistance 
rates showed steadiness towards them over the 
10-year period. Both antibiotics were never used 
in treating UTIs caused by E. coli in The JUH. Never-
theless, Nalidixic acid resistance is rising. Norfloxa-
cin showed favorable susceptibility results and is 
a good candidate for future treatment protocols.
Amoxicillin
A relatively steady resistance is shown between the 
years 2009-2016 with a great decline in resistance 
profile following 2016. This trend is probably in 
relation to the accreditation of AMR plans and the 
restrictions over amoxicillin use as over-the-coun-
ter drug. Though amoxicillin has a high average 
resistance (68.5%), the inclusion of amoxicillin in 
future strategies in treating UTI depends on other 
factors as this antibiotic has minimal side effects 
and a rapid recovery profile, this is consistent with 
its traditional usage as oral treatment of UTI [34]. 
Amoxicillin resistance profile is a good example of 
reversing the resistance process rapidly when the 
selective pressure on the bacteria is eliminated.
Piperacillin/tazobactam and ampicillin
These antibiotics were added to the laboratory pro-
tocols in 2017. There were no significant changes in 
their resistance profiles over the following year with 
average resistance rates of (9.7% and 74.9%) res-
pectively. Previous Jordanian studies reported also 
the prevalence of high resistance rates of E. coli 
isolates to ampicillin over the last 10-year [16, 39]. 
Imipenem, Ertapenem and Meropenem
Overall, the averages of resistance for all carbape-
nems are low (1.2%, 5.1% and 0.3%, respectively). 
Imipenem showed a steady performance against E. 
coli, with a negative annual trend. The restrictions 
applied by infection control departments at The 
JUH on the usage of imipenem as an empirical 
antimicrobial treatment helped in the regression of 
imipenem-resistant E. coli seen in the years 2017 
to 2018. Resistance towards ertapenem showed a 
significant decline over the years between 2010 to 
2018 with a negative overall trend. A progression 
in resistance was noted following the application 
of the new protocols in 2016, which enforces the 
statement that more restrictions should be put on 
prescribing this antibiotic. Ertapenem resistance 
worldwide have shown a significant increase fo-
llowing the year 2015 [35]. Carbapenems should 
be always reserved as the last lines of treatment for 
severe life-threatening cases. We advice the need 
for prudent and rational use of carbapenems in 
our country.
Cephalosporins
ESBLs are most common in E. coli and K. pneu-
moniae. The most typical type of infection they 
cause is urinary tract infections. Also, they can 
cause other serious infections and are most likely 
to be resistant to many of the empirical antibio-
tics used for these infections [36]. Infections with 
ESBL-producers are most common amongst elderly 
people or those who have recently been in hospital 
and received antibiotic treatment. The incidence 
of these infections has been increasing worldwide 
including Jordan [16,36]. Therefore, minimizing the 
spread of resistant organisms relies in part on only 
using antibiotics when necessary and at appropria-
te doses and duration in both the community and 
hospitalized patients [37]. 
First generation cephalosporins
Cephalothin was used widely since mid seventy of 
the last century at The JUH and recently added to 
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the laboratory protocols in 2017. Overall, it shows 
a high resistance profile with average resistance 
of (68.4%).
Second generation cephalosporins
E. coli exhibited a steady resistance profile towards 
cefuroxime over the 10 years period with a minimal 
annual growth rate; hence, cefuroxime is still con-
sidered one of the effective antimicrobials in the 
treatment of UTIs caused by E. coli at The JUH. 
The resistance profile of cefuroxime showed mi-
nimal regression in resistance after applying AMR 
plans during 2016. The latest treatment strategies 
helped in decreasing the selective pressure applied 
by ciprofloxacin and ceftriaxone but led to increa-
se usage of cefuroxime which in turn might lead 
to increased resistance towards it. A relatively high 
average resistance (47.4%) that is trending up might 
enforce a revision of future treatment protocols that 
contain cefuroxime and encourage the switch to 
other drugs in the same class with lower resistan-
ce. Although with minimal variance and mild side 
effects, it is still counted as a recommended drug 
for any future strategies. E. coli exhibited regression 
of resistance towards cefoxitin, with negative overall 
trend of resistance, as the drug has not been availa-
ble for usage in JUH since 2009. Recently in 2018, 
cefoxitin has replaced cefuroxime in many major de-
partments in the hospital in a hope to reduce the 
resistance towards cefuroxime. Rates of resistance 
towards cefuroxime in this study seem to be less 
than worldwide reports [38]. In a former multicenter 
study conducted in Jordan, cefuroxime resistance 
rate was 61.7%, notably, 21.2% were resistant to 
cefoxitin [39]. 
Third generation cephalosporins
An increase in resistance towards cefixime is no-
ted (43.2% to 48.4%) over the 10-year. Though it 
was used in many treatment protocols, it showed 
minimal variance with near steady performance. 
According to low cost and mild side effects, cefixi-
me might play a role in future treatment protocols. 
ceftazidime and cefotaxime were used in the years 
2009-2012 in many treatment protocols at The JUH, 
hence, we can relate the rapid development of re-
sistance seen in these two antibiotics in the years 
mentioned. But since 2012, ceftriaxone largely took 
over and replaced these two antibiotics in all ma-
jor departments in the hospital. Ceftriaxone resis-
tance evolution has a negative trend. Since 2016, 
there were major restrictions on the prescription of 
broad-spectrum antibiotics at The JUH, including 
ceftriaxone with new strategies that encourage the 
use of cefuroxime in the treatment of UTI instead 
of ceftriaxone. This probably helped in regression of 
resistance towards ceftriaxone in the years 2016 to 
2018. ESBL bacteria is the most common cause for 
ceftriaxone resistance [40].
Fourth generation cephalosporins
A significant regression in resistance towards cefe-
pime is evident with a negative overall trend. Ce-
fepime was never available for prescription at The 
JUH after 2009, explaining the significant regression 
of resistance towards this antibiotic. With a high 
average resistance (53.0%) and variance, cefepime 
is not recommended in the near future protocols 
but might be one of our few weapons in the far 
future [41].
Due to the high prevalence of ESBL-positive iso-
lates of E. coli in our region [16, 42]. ESBL test for 
positivity was added to the laboratory protocols in 
May, 2017. Overall, there is a mild increase in the 
percentage of E. coli isolates that showed positivity 
for ESBL testing over a period of 20 months. Strict 
antimicrobial strategies and protocols helped in de-
creasing the development of ESBL positive traits.
According to the data analysis, E. coli has shown 
different degrees of resistance. Understanding the 
patterns of this evolutionary process, the speed of 
it and the variance of growth rates exhibited in 
relation to changing the treatment strategies de-
termines the best drug to use when carrying out 
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continuous analyses of bacterial cultures and their 
antibiotics susceptibility results. 
Recommendations
Summarizes our recommendations, the antimicro-
bials labelled in C are recommended for any ap-
proach to future treatment strategies. The scale 
is based on rationale of antimicrobial stewardship 
strategy formulary restrictions, accredited by Onta-
rio public health [20]. Table 4
Table 4.  Summary of recommendation for future use of antibiotics against E. coli urinary tract infections 






















Amoxicillin 68.5 - (11-20) USD
Diarrhea / Nausea / 
Vomiting
First line agent in UTI 
in pregnancy 
C 0.017
Cefepime 53.0 - (21-30) USD
Positive coombs test 
without hemolysis / 
Rash Diarrhea
First line agent in 
pregnancy 
B 0.004
Cefixime 44.5 + <10 USD
Diarrhea / Fever 
/ Elevated liver 
enzymes /Headache
No current role C 0.026
Cefotaxime 65.9 - (11-20) USD
Nephrotoxicity / 
Fever / Elevated liver 
enzymes / 
Pain at the site of 
injection
No current role B 0.004
Cefoxitin 23.0 - (21-30) USD
GIT upset / Blood 
dyscrasias
Second line agent for 
cystitis 
C 0.001
Ceftazidime 59.0 - >30 USD
Increase in liver 
transaminases 
/ Eosinophilia / 
Phlebitis / Immune 
hypersensitivity 
reactions
No current role B 0.005
Ceftriaxone 65.7 - (21-30) USD
Blood dyscrasias 
/ Elevated liver 
enzymes / Diarrhea 
/ Indurations at the 
site of injection
First line agent in 
severely ill patients 
/ Third line agent in 
pyelonephritis
B 0.004
Cefuroxime 47.4 + <10 USD
GIT upset / Anemia / 
Thrombophlebitis
Second line agent for 
cystitis 
C 0.452
Ciprofloxacin 59.1 - <10 USD
Nausea / Rash / 
Diarrhea
Second line agent for 
pyelonephritis 
B 0.000
Cotrimoxazole 57.1 - <10 USD
Seizure / Immune 
hypersensitivity 
reaction / Fulminant 
hepatic necrosis
First line agent 
for cystitis and 
pyelonephritis
B 0.083
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Ertapenem 5.1 - >30 USD
GIT upset / 







Gentamicin 22.1 - <10 USD
Neurotoxicity /
Nephrotoxicity / 
Ototoxicity / Gait 
instability / Edema / 
Rash / Itching
Second line agent in 
severely ill patients
C 0.039
Imipenem 1.2 - (21-30) USD
Phlebitis / 







Nalidixic acid 62.2 + (11-20) USD
Neurological 
symptoms / GIT 
upset
No current role B 0.002
Nitrofurantoin 20.5 + <10 USD
Methemoglobinemia 
/ Arthralgia / Rash / 
Vasculitis
First line agent for 
cystitis and UTI in 
pregnancy
C 0.095
Norfloxacin 35.5 - <10 USD
Tendinitis / 
Neurological 
symptoms / GIT 
upset / Skin
No current role C 0.816
*: Cost per single antibiotic course, obtained by Jordan University Hospital pharmacy reports of imported drugs quantities in the years 
(2009-2018) (17). 
** level of recommendation: a scale of 6 points represented by the preceding columns was constructed: 2 favorable figures: A, 3 
favorable figures: B, ≥4 favorable figures: C. C code represents our recommendations for the near future protocols. Favorable figures: 
average resistance of less than 50% but higher than 10%, variance of < 0.05, negative trend, cost ≤ (11-20) USD, side effects that do not 
involve major vital organs and narrow spectrum 
Conclusions
We are concluded with significance that gentami-
cin, amoxicillin, cefoxitin and cefixime are the most 
effective antimicrobials to be considered in the fu-
ture treatment protocols based on E. coli resistance 
profile. During the years 2016 to 2018, we found 
that the change in treatment protocols has led to 
significant reduction in the growing resistance of E. 
coli towards some broad-spectrum antibiotics. This 
was a major advancement in the project of finding 
out the ideal strategy in fighting antimicrobial re-
sistance. Due to restrictions against improper pres-
criptions, misuse and overuse of antibiotics, a nota-
ble decline in antimicrobial resistance was achieved 
with a speed that sometimes exceeded the speed 
of acquiring this resistance. This study clearly impli-
cates that E. coli can easily develop resistance in va-
riable degrees among the same class of antibiotics 
necessitating protocols of prescribing antibiotics to 
be directed towards antibiotics individually.
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